Skip to main content
APTXinactive

Aptinyx Inc.

Biopharma developer (SEC filing verified)·Commercial·CEO: Washington Street
OncologyNeurologyImmunologyOphthalmologyCardiovascularInfectious DiseaseMetabolicRespiratoryPainDermatologyNephrologyMusculoskeletal

APTX evidence brief

What we can confirm

BioSniper Score:
6.0 / 10
Lead Asset:
nyx-2925 (Phase 2)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 6.0 / 10 · Lead Asset: nyx-2925 (Phase 2)
BioSniper AIPage evidence connected

Prepared research question

What matters most for APTX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

6.0/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

nyx-2925 (Phase 2)

Next Catalyst

—

Tracking 3 pipeline candidates for Aptinyx Inc..

Similar companies

SILONPHC

Run Aptinyx Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Aptinyx Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is Aptinyx Inc.'s lead drug candidate?

Aptinyx Inc.'s most advanced tracked candidate is nyx-2925 (Phase 2) for Chronic pain (specifically painful diabetic peripheral neuropathy and fibromyalgia).

Who is the CEO of Aptinyx Inc.?

Washington Street is the chief executive officer of Aptinyx Inc. (APTX).

What therapeutic areas does Aptinyx Inc. focus on?

Aptinyx Inc. develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Nephrology, Musculoskeletal.

923 companies304,846 SEC filings22,720 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.